Article Text

Download PDFPDF

98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE)
  1. Joan T Merrill1,
  2. Joshua June2,
  3. Fotios Koumpouras3,
  4. Wambui Machua4,
  5. Mohammed Faisal Khan5,
  6. Anca D Askanase6,
  7. Saira Z Sheikh7,
  8. Arezou Khosroshahi8,
  9. Paul Foster9 and
  10. Debra J Zack9
  1. 1Oklahoma Medical Research Foundation
  2. 2Joshua June, DO
  3. 3Yale Univeristy School of Medicine
  4. 4Piedmont Atlanta Hospital
  5. 5Arthritis and Rheumatology Center of Oklahoma, PLLC
  6. 6Columbia University
  7. 7University of North Carolina at Chapel Hill
  8. 8Emory University
  9. 9Xencor Inc


Background XmAb5871 is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcgammaRIIb. Co-ligation of CD19 and FcgammaRIIb inhibits B lineage cells key to lupus pathogenesis. This Phase 2 study in SLE was designed to minimize background medications and placebo responses to improve interpretation of a small trial in a complex, heterogenous disease.

Methods Patients were enrolled with active, non-organ threatening disease, and treated until improved with 160 mg of IM Depo-Medrol. Immunosuppressive drugs were withdrawn except antimalarials or 10 mg/day prednisone or equivalent before randomization to IV XmAb5871 (5 mg/kg) or placebo. Study treatments were given Q14 days until Day 225 or loss of improvement (LOI), defined as SLEDAI increase 4 points OR new BILAG A or B, with investigator-rated clinical significance. At LOI, patients resumed standard of care. The primary endpoint was the proportion of subjects without LOI by Day 225 in the efficacy evaluable group (those who completed Day 225 or discontinued due to LOI or a drug-related adverse event). Patients who withdrew for other reasons were excluded from this analysis.

Results 104 patients were randomized. In the efficacy evaluable population, 42% of XmAb5871-treated subjects reached Day 225 without LOI vs 28.6% of the placebo group (p=0.18) with 40.4% vs 23.1% (p=0.06) achieving this endpoint in the ITT population. In those with LOI, no (0%) XmAb5871 patients vs 9 (30%) placebo had SLEDAI increase 7 with 3 (13%) vs 7 (23%) developing BILAG A scores. Six XmAb5871-treated patients were withdrawn for infusion-related events. The efficacy evaluable population excluded 10 placebo patients vs 2 XmAb5871 for other reasons, increasing placebo response proportions compared to the ITT population. Time to LOI was significantly longer in XmAb5871-treated patients than placebo (p=0.025, see figure 1).

The most common AEs in XmAb5871-treated patients were transient, infusion-related gastrointestinal side effects during the 1 st or 2nd infusion. There were 8 SAEs in 7 XmAb-treated subjects, 5 in 4 placebo patients, no opportunistic infections, and no deaths. Infection rate was low compared to other SLE trials.

Abstract 98 Figure 1

Kaplan-Meier Probability Plot for Time to LOI in Efficacy Evaluable Populaion

Conclusions Results from this small trial, designed to maximize interpretability, supports further evaluation of XmAb5871 in SLE.

Funding Source(s): This study was funded by Xencor Inc.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.